Oxygen Preconditioning prevents Contrast-Induced Nephropathy after cardiac catheterizatio

Not Applicable

• Conditions: contrast-induced nephropathy

• Registration Number: JPRN-UMIN000012468
• Lead Sponsor: ational Hospital Organization Yokohama Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-12-03
• Study Completion: 2016-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 1300

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with confirmed or suspected acute coronary syndromes (acute myocardial infarction, unstable angina) 2) Patients presenting shock (systolic blood pressure <90 mmHg) 3) Patients with a history of contrast medium allergy 4) Patients for whom the scheduled procedure is a renal artery intervention 5) Patients in whom the only scheduled contrast study is venography at the time of device surgery or catheter ablation 6) Patients with serum creatinine >= 2.5 mg/dL 7) Patients using a contrast medium within 48 h of scheduled cardiac catheterization 8) Patients with respiratory insufficiency (SpO2 < 90%) 9) Patients with PCO2 > 50 mmHg recorded in arterial blood gas analysis at a time when oxygen was not being administered within 1 month of enrollment 10) Patients with chronic obstructive pulmonary disease or patients with risks for CO2 narcosis (including history of CO2 narcosis) 11) Patients receiving home oxygen therapy 12) Patients in whom oxygen is administered at the time of cardiac catheter or within 12 h of cardiac catheter 13) Patients undergoing hemodialysis or peritoneal dialysis 14) Patients who have taken biguanides within 48 h 15) Patients with severe infections, patients in the perioperative period, or those with serious injury, poor nutritional status, in a starvation state, or state of debility 16) Patients with confirmed or suspected rhabdomyolysis 17) Patients with confirmed or suspected pituitary or adrenal insufficiency 18) Patients with paraquat poisoning 19) Patients who are pregnant or may be pregnant 20) Patients from whom consent for participation in this clinical study was not obtained 21) Patients whose doctors judged them as unsuited to participate in this clinical study 22) Patients during the follow-up period of this clinical study or with the history of participation to this clinical study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of CIN within 48 h of cardiac catheterization